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Abstract 
This randomized clinical trial compared cognitive-behavioral therapy (CBT), applied relaxation 
(AR) and wait-list control (WL) in a sample of 65 adults with a primary diagnosis of generalized 
anxiety disorder (GAD). The CBT condition was based on the intolerance of uncertainty model 
of GAD, whereas the AR condition was based on general theories of anxiety. Both manualized 
treatments were administered over 12 weekly one-hour sessions. Standardized clinician ratings 
and self-report questionnaires were used to assess GAD and related symptoms at pretest, 
posttest, and at 6-, 12- and 24-month follow-ups. At posttest, CBT was clearly superior to WL, 
AR was marginally superior to WL, and CBT was marginally superior to AR. Over follow-up, 
CBT and AR were equivalent, but only CBT led to continued improvement. Thus, direct 
comparisons of CBT and AR indicated that the treatments were comparable; however, 
comparisons of each treatment with another point of reference (either waiting list or no change 
over follow-up) provided greater support for the efficacy of CBT than AR. 
 
Key words: Generalized anxiety disorder; cognitive-behavioral therapy; applied relaxation; 
randomized clinical trial; intolerance of uncertainty. 
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A Randomized Clinical Trial of Cognitive-Behavioral Therapy and Applied Relaxation for 
Adults with Generalized Anxiety Disorder 
The diagnostic features of generalized anxiety disorder (GAD) have undergone extensive 
change over the past 20 years. Once thought of as a mild condition characterized by an expansive 
set of anxious symptoms (DSM-III; American Psychiatric Association [APA], 1980), GAD is 
now recognized as a disabling disorder typified by excessive and uncontrollable worry (DSM-
IV-TR; APA, 2000). Accordingly, psychological treatments for GAD have evolved from those 
based on a general understanding of anxiety (e.g., Suinn & Richardson, 1971) to those based on a 
specific conceptualization of pathological worry (e.g., Roemer & Orsillo, 2007). Although it is 
sometimes assumed that the recently-developed interventions lead to better outcomes than the 
earlier treatments, the data thus far have not been convincing. 
Of all general anxiety-reduction strategies, applied relaxation (AR) has received the most 
empirical support in the treatment of GAD. In fact, AR has been identified as one of the few 
empirically-supported treatments for GAD (see Chambless et al., 1998; Chambless & Ollendick, 
2001). Given its long history and demonstrated efficacy, AR has often been compared to other 
anxiety-reduction strategies (see Arntz, 2003; Barlow, Rapee, & Brown, 1992; Öst & Breitholz, 
2000). Taken together, the extant data clearly support the efficacy of AR for the treatment of 
GAD in terms of diagnostic severity, worry, anxiety, depression and general psychopathology. 
 Recently-developed treatments for GAD differ from earlier ones (such as AR) in that 
they specifically target the cognitive, behavioral, and emotional processes thought to underlie 
pathological worry. To our knowledge, Borkovec and Costello (1993) are the only researchers 
who have compared a GAD-specific form of cognitive-behavioral therapy or CBT (based on the 
avoidance model of worry) to AR alone. Although other trials have included GAD-specific 
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forms of CBT and AR (e.g., Borkovec et al., 2002), these trials have combined AR with other 
treatment strategies such as self-control desensitization. Thus, only the Borkovec and Costello 
study allows for a direct comparison of GAD-specific CBT and AR. Overall, the results show 
that CBT and AR were equivalent at posttreatment and that both conditions led to the 
maintenance of treatment gains, with some evidence of further gains in CBT. 
Like Borkovec and others (e.g., Roemer & Orsillo, 2007; Wells, 2006), our group has 
developed a treatment for GAD that is based on a conceptualization of pathological worry. 
Namely, our cognitive model posits that intolerance of uncertainty (a dispositional characteristic 
resulting from negative beliefs about uncertainty and its implications) plays a central role in the 
etiology of GAD by leading to biased cognitive processing. The model also underscores the role 
of positive beliefs about worry, negative problem orientation, and cognitive avoidance (see 
Dugas & Koerner, 2005, for a review). Accordingly, our treatment targets the aforementioned 
cognitive factors and ultimately attempts to aid individuals with GAD to develop beliefs about 
uncertainty that are less negative, rigid, and pervasive. To date, the treatment has been tested in 
three randomized clinical trials. The first study (Ladouceur et al., 2000) revealed that the CBT 
protocol was superior to a wait-list control condition on all outcomes. More importantly, the 
short- and long-term outcomes were at least as good as the best outcomes reported in the 
treatment literature for GAD (for reviews, see Covin, Ouimet, Seeds, & Dozois, 2008; Gould, 
Safren, O’Neill Washington, & Otto, 2004). The second study (Dugas et al., 2003) compared the 
treatment delivered in a group format to wait-list control. Although the findings were similar to 
those obtained in the first trial, one important difference emerged: not only were treatment gains 
maintained over the follow-up period, level of worry decreased from posttreatment to 24-month 
follow-up. Finally, the third study (Gosselin, Ladouceur, Morin, Dugas, & Baillargeon, 2006) 
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contrasted the treatment to nondirective therapy in terms of their impact on medication 
discontinuation in long-term benzodiazepine users. Overall, the treatment was more effective 
than nondirective therapy in helping patients discontinue their use of benzodiazepines. In 
addition, relative to nondirective therapy, the treatment led to greater gains in terms of diagnostic 
remission and symptomatic improvement. 
Although the findings presented above are encouraging, the treatment has yet to be 
compared to a directive and active treatment. Consequently, the main goal of this study was to 
compare the CBT protocol to AR in terms of their short- and long-term benefits and to replicate 
the superiority of both treatments to a wait-list control condition. Given that AR (1) is an 
empirically-supported treatment for GAD (Chambless et al., 1998; Chambless & Ollendick, 
2001); (2) is one of the most commonly administered non-pharmacological interventions for 
GAD (Turner, Beidel, Spaulding, & Brown, 1995); and (3) does not include components that 
overlap with those of our CBT protocol (Dugas & Robichaud, 2007), it was chosen as the 
comparison treatment condition for the current study. To address the study’s main goal, we used 
three experimental conditions: cognitive-behavioral therapy (CBT), applied relaxation (AR), and 
wait-list control (WL). The hypotheses were: (1) that both treatments would be superior to wait-
list at posttest; (2) that CBT would be superior to AR over follow-up; and (3) that CBT (and not 
AR) would lead to continued improvement over follow-up.  
One of the main challenges we faced in designing this study was addressing potential 
allegiance effects. Allegiance effects can occur when researchers wittingly or unwittingly favor a 
condition to which they feel a certain loyalty, such as a treatment they have developed. To 
counter potential allegiance effects, we hired independent assessors (senior doctoral students not 
involved with other aspects of the study) to administer diagnostic interviews and other 
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assessment procedures at all measurement times. The assessors were not involved in treatment 
delivery and were unaware of participants’ experimental condition. We also hired a psychologist 
who had not been trained in CBT – she had received training in psychodynamic therapy – to be 
the main therapist for both treatment conditions. By using a therapist who had not trained in 
CBT, we hoped to both limit allegiance effects and increase the external validity of the study 
(i.e., that its findings would generalize to more therapists, not only those who had extensive 
training in CBT). Finally, we hoped to counter allegiance effects by providing the study’s main 
therapist with weekly clinical supervision by one “expert” in each treatment condition in the 
initial phases of the study (the first author for CBT and the second author for AR). 
Method 
Participants 
The sample (N = 65) consisted of 43 women and 22 men with a primary diagnosis of 
GAD, all of whom were Francophone. Participants had a mean age of 38.5 years (SD = 12.0) and 
an average of 15.3 years of education (SD = 3.4). The ethnic composition of the sample was 91% 
White/European, 5% Middle Eastern, 2% Hispanic, and 2% Asian. In addition, 62.5% of 
participants were employed, 10.9% were students, and 26.6% were unemployed. 
At intake, the mean duration of GAD was 13.9 years (SD = 16.7), and the mean severity 
score for GAD was 5.7 (SD = 1.2) on the 9-point (0 to 8) Clinician’s Severity Rating of the 
Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV; Di Nardo, Brown, & Barlow, 
1994). Comorbid conditions were diagnosed in 58.5% of the sample, with 43.1% having one 
comorbid condition, 10.8% having 2 comorbid conditions, 1.5% having 3 comorbid conditions, 
and 3.1% having 4 comorbid conditions. Secondary conditions were panic disorder with/without 
agoraphobia (n = 27), specific phobia (n = 13), social anxiety disorder (n = 9), dysthymic 
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disorder (n = 8), major depressive disorder (n = 5), obsessive-compulsive disorder (n = 3), and 
hypochondriasis (n = 1). Finally, 55.4% of participants were taking anxiolytic or antidepressant 
medication and 43.1% had previously received CBT for an anxiety or mood disorder. 
Procedure 
Participants were recruited from the Anxiety Disorders Clinic of the Hôpital du Sacré-
Cœur de Montréal and through referrals from general practitioners and mental health specialists 
in the Montreal area. To increase the external validity of the study, media advertisements were 
not used to recruit participants (see Arntz, 2003). All patients referred to our clinic were assessed 
by a team psychiatrist using the Mini International Neuropsychiatric Interview, Version 4.4 
(MINI; Sheehan et al., 1994). Patients who met criteria for primary GAD on the MINI were 
given a consent form explaining the goals and procedures of the study. Those wishing to 
participate in the study were referred for further diagnostic assessment by one of four doctoral 
students with the ADIS-IV. The students received training in the use of the ADIS-IV from the 
study’s primary author who had administered the interview in two previous clinical trials (i.e., 
Freeston et al., 1997; Ladouceur et al., 2000). After the administration of the ADIS-IV, patients 
completed a battery of questionnaires (see Measures).  
Patients who received a primary diagnosis of GAD (the most severe/disabling of all 
diagnosed disorders) on both structured interviews and who also met the study’s other inclusion 
criteria were invited to participate in the study. Inclusion criteria were: (1) a primary diagnosis of 
GAD with a Clinician’s Severity Rating of at least 4/8 (moderate severity); (2) a difference of at 
least 2 points on the Clinician’s Severity Rating between GAD and all comorbid conditions; (3) 
between 18 and 64 years of age; (4) no change in medication type or dose during 4 to 12 weeks 
before assessment (4 weeks for benzodiazepines, 12 weeks for antidepressants and hypnotics); 
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(5) willingness to keep medication stable during the treatment phase of the study (no change in 
medication type or increase in dose); (6) no evidence of suicidal intent; (7) no evidence of 
current substance abuse; and (8) no evidence of current or past schizophrenia, bipolar disorder or 
organic mental disorder. 
Between March 2001 and October 2004, a total of 83 patients were assessed for 
eligibility with the ADIS-IV. Of the 83 patients, 14 were excluded for one of the following 
reasons: GAD was not diagnosed (n = 5); GAD was not the primary diagnosis (n = 5); the 
severity of a comorbid disorder was not at least 2 points less on the Clinician’s Severity Rating 
(n = 2); or a medical problem required immediate attention (n = 2). In addition, 4 patients 
withdrew their consent following the ADIS-IV because of the time commitment required for 
continued participation in the study. 
The 65 participants who made up the final sample were randomly allocated to cognitive-
behavioral therapy (CBT; n = 23), applied relaxation (AR; n = 22) or waiting list (WL; n = 20). 
Allocation concealment and implementation were dealt with as follows: (1) the independent 
diagnostic assessments (MINI and ADIS-IV) were discussed during weekly team meetings; (2) a 
decision was reached to either include or exclude the patient; (3) when a patient was accepted 
into the study, the research coordinator applied a random allocation sequence; (4) following the 
meeting, the psychiatrist who administered the MINI contacted the patient to inform him/her of 
the team’s decision (and of the result of randomization if the patient was accepted into the 
study). The therapy conditions consisted of 12 weekly one-hour sessions with a clinical 
psychologist. Following the 12-week waiting period, wait-list participants were randomly 
allocated to one of the two active treatment conditions, which resulted in 33 participants being 
offered CBT and 31 being offered AR (1 participant dropped out following the 12-week waiting 
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period). The ADIS-IV and all self-report questionnaires were administered at pre-wait-list (for 
wait-list participants), pretreatment, posttreatment, and at 6-, 12-, and 24-month follow-ups. The 
Clinical Global Impression Improvement scale (CGI-I; Guy, 1976) was administered with the 
ADIS-IV at all measurement times. The final follow-up assessment was administered in October 
2006; thus, the total duration of the study was 5 years, 7 months. 
Measures 
Diagnostic and Symptom Measures 
The Mini International Neuropsychiatric Interview, Version 4.4 (MINI; Sheehan et al., 
1994) is a structured diagnostic interview designed for use in research and clinical settings. The 
MINI covers mood disorders, anxiety disorders, substance use disorders, psychotic disorders, 
eating disorders, and suicidal risk. It also includes optional sections for the assessment of other 
related disorders. The MINI has adequate psychometric properties (Sheehan et al., 1997). 
Although the interview typically does not provide severity ratings, we used the 9-point 
Clinician’s Severity Rating scale (see ADIS-IV, below) to obtain information about the severity 
of MINI diagnoses. By having independent raters provide severity ratings using two interviews, 
we were able to compute inter-rater agreement on the severity of diagnosed conditions – rather 
than limiting agreement calculations to the presence/absence of conditions. The Anxiety 
Disorders Interview Schedule for DSM-IV (ADIS-IV; Di Nardo et al., 1994) assesses anxiety 
disorders, and screens for mood disorders, somatoform disorders, psychoactive substance use 
disorders, psychotic disorders, and medical problems. The interview provides information on the 
presence of Axis I disorders with severity ratings on a 9-point Clinician’s Severity Rating scale 
ranging from 0 (absent or none) to 8 (very severe or very severely disturbing/disabling), with a 
rating of 4 (moderate or definitely disturbing/disabling) corresponding to the threshold of clinical 
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significance. In the remainder of the text, the Clinician’s Severity Rating from the ADIS-IV will 
simply be referred to as the CSR. Brown, Di Nardo, Lehman and Campbell (2001) found that the 
diagnostic reliability of the anxiety disorders obtained with the ADIS-IV is good, with 
improvements over the ADIS-R (Di Nardo & Barlow, 1988). 
The Penn State Worry Questionnaire (PSWQ; Meyer, Miller, Metzger, & Borkovec, 
1990) includes 16 items that assess excessive and uncontrollable worry. Items are rated on a 5-
point scale, ranging from 1 (not at all typical of me) to 5 (very typical of me). The PSWQ has 
high internal consistency,  = .86 to .95, and good test-retest reliability over four weeks, r = .74 
to .93 (Molina & Borkovec, 1994). It also shows evidence of convergent, divergent and 
discriminant validity in nonclinical and clinical populations (Brown, Antony, & Barlow, 1992; 
Meyer et al., 1990; Molina & Borkovec, 1994). In the current sample, the internal consistency of 
the PSWQ was  = .83. The Worry and Anxiety Questionnaire (WAQ; Dugas et al., 2001) 
contains 11 items covering DSM-IV diagnostic criteria for GAD. Previous research shows that 
the WAQ has good known-groups validity and satisfactory test-retest reliability over nine weeks 
(diagnostic sensitivity: 75%; diagnostic specificity: 82%; Dugas et al., 2001). To complement the 
PSWQ and to allow for comparisons with our previous treatment studies, only the Somatic 
subscale of the questionnaire (WAQ-Som) was retained for the current study. The WAQ-Som 
assesses the presence/severity of each somatic symptom of GAD on a 5-point scale ranging from 
1 (not at all) to 5 (very severely). The internal consistency of the WAQ-Som in the present 
sample was  = .71. 
Ancillary Measures 
The State Trait Anxiety Inventory (Form Y), Trait version (STAI-T; Spielberger, 1977) is 
a 20-item measure of individual differences in anxiety proneness or trait anxiety. Each item is 
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rated on a 4-point scale, ranging from 1 (almost never) to 4 (almost always). The STAI-T has 
high internal consistency in anxiety disorder samples,  = .89, and has been shown to reliably 
distinguish between patients with anxiety disorders and nonclinical controls (Bieling, Antony, & 
Swinson, 1998). In the current sample, the internal consistency of the STAI-T was  = .86. The 
Beck Depression Inventory II (BDI-II; Beck, Steer, & Brown, 1996) includes 21 groups of 4 
items reflecting different degrees of depressive symptoms (e.g., sadness, pessimism, loss of 
interest). Respondents indicate which item within each group best describes them during the past 
two weeks, with scores ranging from 0 to 3. The BDI-II has very good internal consistency,  = 
.92, and excellent test-retest reliability over a one-week period, r = .93 (Beck et al., 1996). The 
questionnaire also shows evidence of convergent and divergent validity (Steer & Clark, 1997). 
The internal consistency of the BDI-II was  = .87 in the present sample. The Clinical Global 
Impression, Improvement scale (CGI-I; Guy, 1976) assesses the degree of change in a patient’s 
overall condition relative to baseline. In the present study, global change was rated on a 7-point 
scale ranging from 1 (very much improved) to 7 (very much worse). The CGI-I is a sound 
measure of global change and is sensitive to the effects of treatment (Leucht & Engel, 2006; 
Zaider, Heimberg, Fresco, Schneier, & Liebowitz, 2003). 
Measures of Common Therapy Factors 
The Credibility and Expectancy Scale for GAD (CES-GAD; Ladouceur et al., 2000), 
which is based on the CES (Borkovec & Nau, 1972), contains 6 items that measure the 
credibility of the treatment and participant expectations of therapeutic change with regards to the 
symptoms of GAD (whereas the original CES refers to the fear of public speaking). Items are 
rated on a 5-point scale ranging from 1 (extremely weak) to 5 (extremely strong). The internal 
consistency of the CES was  = .86 in the original validation study (Borkovec & Nau), and the 
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internal consistency of the CES-GAD was  = .80 in the current study. The Nijmegen Motivation 
List (NML; Keijsers, Hoogduin, & Schaap, 1991) includes 17 items, rated on a 5-point scale 
ranging from 1 (not at all applicable to me) to 5 (completely applicable to me), that assess 
treatment motivation. The NML has weak to acceptable internal consistency, ranging from  = 
.53 to .66. In the current sample, the internal consistency of the NML was acceptable at  = .63. 
Finally, the Therapist Rating Scale (TRS; Williams & Chambless, 1990) is made up of 25 items 
that assess participant perceptions of the following therapist characteristics: caring/involved, 
modeling self-confidence, unconditionally accepting, challenging, explicit, and willing to be 
known. Each item is rated on a 7-point scale ranging from 1 (strongly agree) to 7 (strongly 
disagree). The TRS subscales have good internal consistency,  = .71 to .94, and the scale has 
adequate test-retest reliability over 2 to 4 weeks, τ = .44 to .66 (Williams & Chambless, 1990). 
The internal consistency of the TRS was  = .77 in the current study. We have used all three 
measures of common therapy in our previous treatment studies of GAD (Dugas et al., 2003; 
Gosselin et al., 2006; Ladouceur et al., 2000). 
Therapists 
The study’s main therapist (Renée Leblanc), who treated 61 of the 65 participants, was a 
licensed psychologist who had not received extensive training in CBT – her graduate level 
training had been in the area of psychodynamic therapy. At the outset of the study, she had 5 
years of clinical experience, which was the result of holding a part-time private practice for 
mood, anxiety, and adjustment disorders. She was trained using the CBT and AR treatment 
manuals, and weekly supervisions were held with the senior study authors. Specifically, the 
therapist received about eight hours of formal training in each treatment condition (from the first 
author for CBT from the second author for AR). In addition, she received about one hour of 
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weekly supervision in each treatment condition for the duration of the study (with most of the 
CBT supervision provided by the first author and most of the AR supervision provided by the 
second author). To further facilitate the training of the main therapist, the first author treated 4 
participants (2 in each condition) during the early stages of the study – this allowed the main 




Cognitive-behavioral therapy consisted of 12 weekly one-hour sessions and covered the 
following treatment phases. (1) Psychoeducation and worry awareness training (1 session): The 
therapist first explained that the goal of CBT was to learn to recognize and reduce worry, thereby 
decreasing overall levels of worry, anxiety, and tension. Patients learned to monitor their 
worrying on a day-to-day basis, and to distinguish between worries about current problems (e.g., 
meeting deadlines at work) and worries about hypothetical situations (e.g., being involved in an 
accident). (2) Uncertainty recognition and behavioral exposure (3 sessions): The therapist then 
helped patients to understand the role of intolerance of uncertainty in worry and anxiety, to 
realize that uncertainty-inducing situations are largely unavoidable, to recognize the various 
manifestations of intolerance of uncertainty, and to seek out and experience uncertainty-inducing 
situations. (3) Reevaluation of the usefulness of worry (1 session): In the next treatment phase, 
patients learned to identify and reevaluate their positive beliefs about worry (e.g., “my worries 
prepare me for bad things that might happen”) using strategies such as the lawyer-prosecutor role 
play. (4) Problem-solving training (3 sessions): Patients then learned to address worries about 
current problems by using a problem-solving procedure targeting problem orientation, problem 
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definition and goal formulation, generation of alternative solutions, decision making, and 
solution implementation and verification (see D’Zurilla, 1986). (5) Imaginal exposure (3 
sessions): Finally, patients learned to use imaginal exposure for worries about hypothetical 
situations. With the help of the therapist, patients developed a scenario describing their worst 
fear using the downward arrow technique, and recorded the scenario on a looped tape for 
repeated exposure. They then listened to the recording for 20 to 60 minutes (long enough to 
experience a decrease in anxiety) everyday and continued to “expose” themselves to the scenario 
until it no longer provoked anxiety (typically 10 to 15 exposure sessions). See Dugas and 
Robichaud (2007) for a detailed description of the CBT protocol. 
Applied Relaxation 
Applied relaxation also consisted of 12 weekly one-hour therapy sessions covering the 
following treatment phases. (1) Psychoeducation and tension awareness training (1 session): 
During the first phase of treatment, the therapist explained that the goal of AR was to learn to 
recognize muscle tension and to apply relaxation methods, thereby reducing overall levels of 
tension, anxiety, and worry. Patients also learned to monitor their levels of muscle tension on a 
daily basis. (2) Tension-release training (4 sessions): Patients learned to tense then relax 
different muscle groups (moving from 16 to 4 muscle groups) until full relaxation was achieved. 
(3) Relaxation by recall (2 sessions): Once the tension-relaxation procedure with 4 muscle 
groups had been mastered, patients learned to relax their muscles without tensing them first. (4) 
Relaxation by counting (1 session): At the end of sessions when patients had achieved full 
relaxation through recall alone, the therapist slowly counted from one to ten, asking patients to 
imagine their relaxation becoming even deeper. Once the patients had successfully integrated the 
counting into the recall procedure, they learned to relax by counting alone. (5) Conditioned 
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relaxation (3 sessions): In this phase of treatment, patients learned to apply relaxation skills in 
everyday situations using a graded hierarchy. This enabled them to achieve relaxation in 
response to a self-produced cue (e.g., by counting to ten) in real-life stressful situations. For a 
detailed description, see Bernstein and Borkovec (1973) and Öst (1987). 
For both CBT and AR, the final session was devoted to the prevention of relapse. Patients 
were encouraged to regularly evaluate their success in using the treatment strategies and to 
persevere when things became difficult. Both treatment conditions also made use of standard 
forms for the between-session exercises to increase compliance with therapist recommendations. 
Finally, at the end of each phase of CBT and AR, patients received a written summary describing 
the main issues addressed in that particular segment of treatment. By the end of therapy, patients 
had a complete manual that could be used as a relapse prevention guide. 
Waiting List 
The duration of the wait-list condition was 12 weeks. Wait-listed participants were 
contacted by telephone every three weeks by the psychiatrist who had administered the MINI to 
monitor their state. 
Results 
Diagnostic Reliability 
Inter-rater agreement for the primary diagnosis on the MINI and the ADIS-IV was 
examined to determine diagnostic reliability. Criteria for inter-rater agreement were (1) 
concurrence of primary diagnosis and (2) agreement on severity of primary diagnosis (defined as 
a difference of no more than 1 point on the severity scales of the interviews). Using these criteria 
for diagnostic agreement, we calculated kappa scores and obtained values of κ = .66 for all 83 
patient interviews and κ = .70 for the interviews of the final 65 patients.  
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Treatment Integrity 
Intervention checklists were adapted from our earlier studies to assess treatment integrity. 
The checklists closely followed the treatment manuals, including the structure of the session and 
the information to be presented and discussed. Treatment integrity was assessed by a research 
assistant who listened to audiotapes of all sessions for 4 randomly-selected participants in each 
condition. The assistant rated the therapist’s interventions against the intervention checklist and 
noted whether every item was properly addressed. Treatment integrity was 90.1% in the CBT 
condition and 93.1% in the AR condition. 
Short-Term Outcome: CBT, AR and WL 
Table 1 presents means and standard deviations on the outcome measures at pre and 
posttest in each condition. Seven (7) participants did not complete the first 12 weeks of the 
study; 2 dropped of CBT and 5 dropped out of AR (there were no drop-outs in the WL 
condition). Missing posttest data were replaced with pretest scores. Thus, the data presented in 
Table 1 (and the pre to posttest analyses) are based on the intent-to-treat sample.  
We conducted preliminary analyses on a wide range of variables to see if participants in 
the three conditions were comparable at intake. No between-group differences were found for 
demographic variables (age, sex, ethnic origin, years of education, and employment status), 
clinical variables (duration of GAD, number of comorbid conditions, medication status, and 
previous psychotherapy), and outcome variables (CSR, PSWQ, WAQ-Som, STAI-T, and BDI-
II). Pre to posttest analyses were therefore conducted without controlling for these variables. 
Given that we were interested in comparing each treatment condition to WL (see 
Hypothesis 1), we ran two sets of analyses, the first comparing CBT to WL and the second 
comparing AR to WL. In each case, we ran 2 Group X 2 Time ANOVAs for each of the first five 
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measures, and a between-subjects ANOVA for the CGI-I. For each set of analyses, Bonferroni 
corrections were applied and significance levels were adjusted to p < .008. The first set of 
analyses revealed that CBT was superior to WL on four measures: CSR, F (1, 41) = 24.67, p < 
.001, partial 
2
 = .38; PSWQ, F (1, 41) = 25.30, p < .001, partial 
2
 = .38; WAQ-Som, F (1, 40) 
= 8.87, p = .005, partial 
2
 = .18; and CGI-I, F (1, 41) = 13.87, p = .001, partial 
2
 = .25. In the 
second set of analyses, AR was superior to WL on one measure: CSR, F (1, 40) = 8.27, p = .006, 
partial 
2
 = .17. Thus, relative to WL, although both treatments led to greater change on overall 
severity of GAD, only CBT led to greater change on pathological worry, somatic symptoms of 
GAD, and global clinical improvement. Finally, compared to WL, neither treatment led to 
superior outcomes on trait anxiety or depressive symptoms from pre to posttest. 
We also used one-way within-subjects ANOVAs to test for changes in each outcome 
measure within each experimental condition and found significant decreases on every measure in 
the CBT and AR conditions, as well as significant decreases on two measures (CSR, WAQ-Som) 
in the WL condition. Table 2 presents pre to posttest effect sizes.  
Short-Term Outcome: CBT and AR 
Following a 12 week delay, wait-listed participants were randomly allocated to one of the 
two treatment conditions, which yielded a final CBT sample of n = 33 and a final AR sample of 
n = 31 (one participant dropped out after the post wait-list assessment). Preliminary analyses 
were carried out to ensure that participants in the two treatment conditions were comparable at 
pretreatment. Again, we observed no between-group differences for demographic, clinical, and 
outcome variables. Furthermore, all participants completed the measures of treatment credibility 
and expectancy (CES-GAD), treatment motivation (NML) and therapist characteristics (TRS) 
after the third treatment session. In the CBT condition, mean scores were 24.78 (SD = 2.86) for 
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the CES-GAD, 67.78 (SD = 6.07) for the NML, and 59.62 (SD = 10.84) for the TRS. Participants 
in the AR condition had mean scores of 23.38 (SD = 3.41) for the CES-GAD, 66.68 (SD = 6.50) 
for the NML, and 59.83 (SD = 12.33) for the TRS. One-way ANOVAs revealed no significant 
between-group differences on any of the measures of common therapy factors. Thus, pre to 
posttreatment analyses comparing the active treatment conditions did not control for 
demographic, clinical and outcome variables, as well as common therapy factors. 
Two-way repeated measures ANOVAs comparing the treatment conditions from pre to 
posttreatment were carried out on each outcome measure (with the exception of the CGI-I). For 
each measure, we found significant within-group effects (with improvements on all variables), 
nonsignificant between-group effects, and nonsignificant Group X Time interactions. A one-way 
ANOVA comparing both treatment conditions at posttreatment revealed a significant between-
group difference on the CGI-I, F (1, 62) = 6.05, p < .05, partial 
2
 = .09, with participants in the 
CBT condition showing greater improvement than those in the AR condition. Thus, although 
analyses involving measures of specific symptoms suggested that the treatment conditions led to 
similar change, ratings of global improvement suggested that CBT resulted in greater positive 
change than did AR. 
Long-Term Outcome 
Means and standard deviations on the outcome measures at all measurement times in the 
treatment conditions are presented in Table 3. Long-term outcomes were assessed by conducting 
growth curve analyses.  Specifically, we used the multilevel modeling program Hierarchical 
Linear Modeling (HLM 6.04; Raudenbush, Bryk, & Congdon, 2005) to compute growth curves 
for each participant. The effect of time was assessed using participants’ scores at posttreatment, 
and at 6-, 12- and 24-month follow-ups. Separate analyses were conducted for each of the study 
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measures. Long-term outcomes were assessed in two ways: (1) by comparing the slopes for each 
measure in both conditions; and (2) by comparing the slopes for each measure in each condition 
to a slope of zero.  
To test Hypothesis 2 (that CBT would be superior to AR over follow-up), we calculated 
and contrasted the slopes for each measure from posttreatment to 2-year follow-up in both 
conditions. All between-group comparisons of slopes revealed non-significant findings. To test 
Hypothesis 3 (that CBT, and not AR, would lead to continued progress over follow-up), we 
compared the slope for each measure in each condition with a slope of zero (a slope of zero 
denotes no change over time). In the CBT condition, the slopes for three measures were 
significantly different from a slope of zero: the PSWQ slope, coefficient = -1.98, t (30) = -3.99, p 
< .001, the STAI-T slope, coefficient = -1.33, t (30) = -2.64, p < .05, and the CGI-I slope, 
coefficient = -.14, t (30) = -2.28, p < .05. For each of these three measures, the results point to 
continued improvement over the 2 years following the end of treatment for CBT participants. In 
the AR condition, none of the slopes were significantly different from a slope of zero.  
Diagnostic Remission 
In line with current recommendations on the use the ADIS-IV, diagnostic remission was 
defined as having a Clinician’s Severity Rating of 3 or less for GAD. In the CBT condition, 
remission rates for GAD were 70% at posttreatment, 76% at 6-month follow-up, 84% at 12-
month follow-up, and 77% at 24-month follow-up. In the AR condition, remission rates for GAD 
were 55% at posttreatment, 70% at 6-month follow-up, 68% at 12-month follow-up, and 61% at 
24-month follow-up. Chi-square tests comparing remission rates in both conditions revealed 
nonsignificant results at every time point. 
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In terms of additional diagnoses, we used HLM to assess change over time from 
pretreatment to 2-year follow-up in the number of additional diagnoses in each treatment 
condition. The CBT and AR slopes were not significantly different from each other, suggesting 
that the number of additional diagnoses was not differentially impacted by the treatment 
conditions. Furthermore, in both CBT and AR, the slopes for number of additional diagnoses 
were not significantly different from a slope of 0, indicating that the number of diagnoses was 
unaffected by each of the treatment conditions.  
Medication 
Medication use was scored as a dichotomous variable (0 = no medication use; 1 = 
medication use) at each study time point. In the CBT condition, percentages of participants 
taking anxiolytic or antidepressant medication were 58% at pretreatment, 52% at posttreatment, 
46% at 6-month follow-up, 45% at 12-month follow-up, and 36% at 24-month follow-up. In the 
AR condition, percentages were 58% at pretreatment, 50% at posttreatment, 57% at 6-month 
follow-up, 67% at 12-month follow-up, and 46% at 24-month follow-up. Change in medication 
status was assessed by using HLM to examine medication use from pretreatment to 24-month 
follow-up in each treatment condition. When the slopes for the treatment conditions were 
compared, they were not significantly different. Finally, in both AR and CBT, the slopes for 
medication use were not significantly different from a slope of 0, suggesting that use of 
medication was unaffected by each of the treatments. 
Discussion 
The current study compared the efficacy of cognitive-behavioral therapy and applied 
relaxation for generalized anxiety disorder. The study also included a wait-list control condition 
to confirm each treatment’s efficacy. The first hypothesis (that both treatments would be superior 
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to wait-list at posttest) received partial support. Although the data supported the superiority of 
CBT over WL, they offered only limited support for the superiority of AR over WL. The second 
hypothesis (that CBT would be superior to AR over follow-up) was not supported, whereas the 
third hypothesis (that only CBT would lead to continued progress over follow-up) was 
supported. In the following paragraphs, we discuss the implications of these findings. 
Short-Term Outcomes 
CBT was superior to WL on 4 of 6 outcomes: overall severity of GAD, pathological 
worry, somatic symptoms of GAD, and global clinical improvement. However, CBT was not 
superior to WL in terms of pre to posttest change on trait anxiety and depressive symptoms. 
Consequently, this study did not replicate earlier findings showing that the same CBT protocol 
was superior to WL on general anxiety and depressive symptoms (Dugas et al., 2003; Ladouceur 
et al., 2000). The different measures used in the studies (the previous studies used the Beck 
Anxiety Inventory and the BDI, whereas this study used the STAI-T and the BDI-II) may have 
contributed to the inconsistent findings. In particular, the STAI-T, which some authors consider 
to be a measure of negative affect (e.g., Bieling et al., 1998; Watson & Clark, 1984), may be less 
sensitive to change than the BAI, which is primarily a measure of somatic anxiety (see Cox, 
Cohen, Direnfeld, & Swinson, 1996; Keedwell & Snaith, 1996). Overall, however, the data from 
the current study lend further support to the efficacy of CBT, in particular with regards to the 
symptoms of GAD and global improvement. 
AR was superior to WL on only 1 outcome, namely overall severity of GAD as assessed 
by the Clinician’s Severity Rating of the ADIS-IV. Thus, the data offered limited support for the 
superiority of AR over WL in terms of short-term improvement. At first glance, these findings 
appear to be at odds with previous studies (e.g., Barlow et al., 1992; Borkovec & Costello, 1993) 
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that clearly support the efficacy of AR for the treatment of GAD. However, one must keep in 
mind that wait-listed participants made substantial improvements in the current study, more than 
what is typically observed in the treatment literature on GAD. For example, the WL condition 
generated a mean effect size of partial 
2
 = .18 for all pre to posttest assessments, as well as 
significant improvements on two measures (overall severity of GAD and somatic symptoms of 
GAD). Thus, although we did not find strong support for the superiority of AR over WL, it 
appears that the assessment of the short-term efficacy of AR (and CBT) was biased by the 
unusually large gains made by the wait-listed participants.  
When CBT and AR were directly compared in terms of pre to posttreatment change, only 
one significant finding emerged: CBT was superior in terms of global clinical improvement. It is 
somewhat surprising that CBT did not lead to statistically greater change in worry (as assessed 
by the PSWQ), which is not directly addressed by AR. One possible explanation for this result is 
that GAD, like other anxiety disorders, involves a process of interacting cognitive, physiological, 
affective and behavioral systems (Beck & Clark, 1997; Borkovec et al., 2002), which implies 
that change in one system typically leads to changes in others. Consequently, although AR may 
have initially generated changes in somatic symptoms such as muscle tension, these initial 
changes may have subsequently led to changes in worry. Interestingly, the finding that AR did 
not generate greater change than CBT on somatic symptoms (as assessed by the WAQ-Som) can 
also be accounted for by the notion of interacting systems. 
Long-Term Outcomes 
When we compared the long-term outcomes of participants in the CBT and AR 
conditions, we found no significant between-group differences. These finding are somewhat at 
odds with those of Borkovec and Costello (1993), who found evidence for the superiority of 
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CBT over AR at 12-month follow-up. One could argue that studies with larger samples sizes 
would help clarify the long-term outcomes associated with CBT and AR. Of course, one could 
also argue that the current study’s sample size (n = 33 for CBT; n = 31 for AR) and follow-up 
strategy (3 assessments over 2 years) should be sufficient to detect patterns that have practical 
implications for clinical practice. Either way, one thing seems clear: in terms of direct 
comparisons, the findings suggest that the treatments tested in the current study lead to similar 
short- and long-term outcomes.  
When the slopes of participants in the CBT condition were compared to a slope of 0 (no 
change), the results revealed that treated participants made further progress during the follow-up 
phase of the study. Specifically, further gains were noted on the measures of pathological worry, 
trait anxiety and global clinical improvement. It is noteworthy that a previous study (Dugas et al., 
2003) also found that this CBT protocol led to further decreases in worry in the 2 years following 
treatment termination. Thus, it appears that the CBT protocol tested in the current study helps 
patients with GAD to significantly decrease their level of worry over the course of treatment and 
continue to decrease their worry following treatment termination. It may be that recognizing, 
accepting and dealing with uncertainty is a complex task that requires exposure to a wide variety 
of uncertainty-inducing situations over an extended period of time. Consequently, although 
patients begin to change their uncertainty-related beliefs, appraisals, and behaviors over the 
course of therapy, this multifaceted change process may very well continue following treatment 
termination as the individual is faced with a broad array of new and challenging situations. 
When the long-term outcomes of participants in AR were contrasted with a no-change 
condition (a slope of 0), no significant findings emerged. In other words, participants treated 
with AR maintained their treatment gains over the 2-year follow-up on every outcome. In fact, 
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for every measure, the follow-up slope was a negative one, suggesting that a larger sample would 
not have revealed a pattern of relapse – in fact, a larger sample may have exposed further 
progress following treatment. At the very least, the data suggest that AR leads to the 
maintenance of treatment gains following treatment, which is in line with previous clinical trials 
of AR for GAD (e.g., Arntz, 2003; Barlow et al., 1992; Borkovec & Costello, 1993; Öst & 
Breitholtz, 2000). 
Overall, the results of the current study can be interpreted in different ways. On the one 
hand, direct comparisons of CBT and AR revealed only one significant finding: CBT led to 
greater change in global clinical improvement from pre to posttreatment. All other direct 
comparisons of CBT and AR indicated that the treatments produce similar short- and long-term 
outcomes. Thus, in terms of direct comparisons, the weight of the evidence indicates that CBT 
and AR are equivalent. On the other hand, CBT was superior to WL on 4 of 6 outcomes whereas 
AR was superior to WL on only 1 outcome. In addition, CBT led to continued improvement on 3 
outcomes over follow-up whereas AR did not lead to continued improvement following 
treatment. Thus, comparisons of each treatment with another point of reference (either waiting 
list or no change over follow-up) provide greater support for the efficacy of CBT than AR. 
Perhaps the most appropriate interpretation for the overall pattern of findings is that CBT and 
AR lead to outcomes that are more similar than different. Given the well-documented efficacy of 
AR in the treatment of GAD (Chambless et al., 1998; Chambless & Ollendick, 2001), this 
conclusion is not entirely surprising. 
One implication of the current findings is that the CBT protocol may need to be revised 
to more fully meet the needs of individuals with GAD. In particular, recent data suggest that a 
greater focus on the interaction between intolerance of uncertainty and fear of anxiety (Buhr & 
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Dugas, in press) may be beneficial. As discussed elsewhere (Dugas & Koerner, 2005; Koerner & 
Dugas, 2006), GAD may be characterized by conflicting cognitive-motivational states resulting 
from high levels of intolerance of uncertainty and fear of anxiety. Specifically, intolerance of 
uncertainty may promote the use of approach behaviors to attain a sense of certainty, and fear of 
anxiety may promote the use of avoidance strategies to inhibit the experience of anxious arousal. 
By directly addressing these conflicting cognitive-motivational states, we may be able to 
increase the efficacy of treatment.  
This study had a number of limitations; the first being that allegiance effects may have 
biased the comparison of the treatment conditions. Considering that the CBT protocol was 
initially developed by the first author (Dugas & Ladouceur, 2000), we may have unwittingly 
favored CBT over AR in some way. A second limitation of the study is that a single therapist 
treated 61 of 65 participants. Because one therapist treated almost all participants, we cannot 
assess the extent to which the findings reflect the specific treatments as opposed to the 
characteristics of the therapist. Relatedly, we did not assess the competency of the therapist, 
which is a notable limitation of the study (ideally, treatment studies should assess both integrity 
and competency). Had we used more therapists, and measured competency in addition to 
integrity, the utility and generalizability of the findings would have been greater. 
A third limitation relates to the reliability of the diagnoses. Because the ADIS-IV was 
only administered to patients having received a diagnosis of GAD on the MINI, the results of the 
ADIS-IV could have been influenced by demand characteristics. Likewise, given that the 
assessors were aware that a severity score difference of at least 2 points on the CSR of the ADIS-
IV was required for inclusion in the study, the frequency of such an occurrence may have 
increased. A final limitation of note is the relatively small sample size. Although the size of the 
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sample was larger than all but one previous study comparing CBT and AR (Barlow et al., 1992, 
had the same number of participants), a larger sample would have nonetheless been helpful for 
some analyses. 
In summary, the results of the present study indicate that CBT and AR are efficacious 
treatments for GAD. The findings also suggest that although both treatments produce similar 
outcomes, only CBT appears to lead to continued improvement following treatment termination. 
Nonetheless, one thing seems clear: given that treatments developed specifically for GAD lead to 
full remission in only about half to two-thirds of patients (Fisher, 2006), much work remains to 
be done. 
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Table 1 
Means and Standard Deviations on Outcome Measures in Each Experimental Condition at Pre 
and Posttest 
 
 Pretest Posttest 
 (n = 65) (n = 65) 
Measure and condition M SD M SD 
 
CRS 
CBT 5.78 1.04 1.61 2.21 
AR 5.36 1.26 2.55 2.58 
WL 5.90 1.25 4.78 2.07 
PSWQ 
CBT 61.65 8.27 51.13 9.87 
AR 58.01 5.51 52.16 8.04 
WL 57.34 9.78 58.80 9.13  
WAQ-Som 
CBT 21.13 4.07 17.74 4.45 
AR 20.82 5.48 17.91 4.81 
WL 22.42 3.17 21.45 3.65  
STAI-T 
CBT 53.04 7.30 46.35 7.99 
AR 52.23 7.15 46.95 8.42 
WL 52.06 9.62 48.98 8.68  
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BDI-II 
CBT 15.36 8.20 8.83 6.63 
AR 16.65 9.27 10.27 8.99 
WL 13.70 7.72 11.20 7.26  
CGI-I 
CBT - - 2.35 0.94 
AR - - 2.77 1.02  
WL -* - 3.35 0.81  
 
Note. CSR = Clinician’s Severity Rating from the Anxiety Disorders Interview Schedule for 
DSM-IV; CBT = cognitive-behavioral therapy; AR = applied relaxation; WL = waiting list; 
PSWQ = Penn State Worry Questionnaire; WAQ-Som = Worry and Anxiety Questionnaire, 
Somatic subscale; STAI-T = State-Trait Anxiety Inventory, Trait version; BDI-II = Beck 
Depression Inventory II; CGI-I = Clinical Global Impression, Improvement subscale. 
* CGI-I scores cannot be calculated until the second assessment.  
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Table 2 
Pre to Posttest Effect Sizes (Partial 
2
) in the CBT, AR, and WL Conditions 
 
 CBT AR WL 
Measures 
 
CSR 0.76 0.62 0.39 
PSWQ 0.74 0.34 0.03 
WAQ-Som 0.61 0.37 0.23 
STAI-T 0.55 0.36 0.16 
BDI-II 0.55 0.49 0.10 
 
Note. CBT = cognitive-behavioral therapy; AR = applied relaxation; WL = waiting list; CSR = 
Clinician’s Severity Rating from the Anxiety Disorders Interview Schedule for DSM-IV; PSWQ 
= Penn State Worry Questionnaire; WAQ-Som = Worry and Anxiety Questionnaire, Somatic 
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Table 3 
Means and Standard Deviations on Outcome Measures in the Treatment Conditions at Pretest, Posttest and Follow-Ups 
 
 Pretest Posttest 6 months 12 months 24 months 
 (n = 64) (n = 64) (n = 50) (n = 50) (n = 42) 
Measure and condition M SD M SD M SD M SD M SD 
 
CSR 
CBT 5.44 1.21 1.73 2.23 1.33 1.86 1.00 1.60 1.21 1.75 
AR 5.16 1.81 2.55 2.55 1.43 1.88 1.57 1.91 1.21 2.08 
PSWQ 
CBT 60.76 8.88 50.79 10.24 48.70 10.33 45.83 8.67 45.30 8.01 
AR 58.20 6.48 51.21 7.90 49.09 7.49 46.74 8.61 48.17 11.72 
WAQ-Som 
CBT 21.06 4.02 17.36 5.03 15.63 4.12 14.90 4.99 15.63 4.84 
AR 21.00 4.83 17.94 4.40 18.22 4.78 15.89 4.03 15.77 5.17 
STAI-T 
CBT 51.06 7.87 45.45 9.11 43.30 9.68 41.38 8.79 41.93 9.29 
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AR 51.94 7.90 46.03 9.75 45.52 9.10 43.16 8.39 43.54 9.39 
BDI-II 
CBT 13.67 7.91 8.70 6.89 7.81 7.45 6.52 5.27 6.81 5.59 
AR 15.07 9.08 9.71 8.74 8.00 6.90 6.74 7.83 6.46 5.47 
CGI-I 
CBT - - 2.24 0.90 1.96 0.76 1.69 0.97 1.75 0.84 
AR -* - 2.84 1.04 2.04 1.11 2.10 0.83 1.93 1.21 
 
Note. CSR = Clinician’s Severity Rating from the Anxiety Disorders Interview Schedule for DSM-IV; CBT = cognitive-behavioral 
therapy; AR = applied relaxation; PSWQ = Penn State Worry Questionnaire; WAQ-Som = Worry and Anxiety Questionnaire, 
Somatic subscale; STAI-T = State-Trait Anxiety Inventory, Trait version; BDI-II = Beck Depression Inventory II; CGI-I = Clinical 
Global Impression, Improvement subscale. 
* CGI-I scores cannot be calculated until the second assessment.  
